EntryPoint Capital LLC Acquires New Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

EntryPoint Capital LLC purchased a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 9,636 shares of the company’s stock, valued at approximately $109,000.

A number of other institutional investors have also bought and sold shares of the company. Quarry LP bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $48,000. China Universal Asset Management Co. Ltd. increased its stake in Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after buying an additional 5,037 shares during the last quarter. Jump Financial LLC purchased a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $114,000. Trexquant Investment LP purchased a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $114,000. Finally, Acadian Asset Management LLC purchased a new stake in Centessa Pharmaceuticals in the 1st quarter valued at about $330,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 4.8 %

CNTA opened at $10.78 on Friday. The company has a 50 day moving average of $9.10 and a 200 day moving average of $9.55. Centessa Pharmaceuticals plc has a 12 month low of $5.15 and a 12 month high of $12.45. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. Equities analysts expect that Centessa Pharmaceuticals plc will post -1.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on CNTA shares. BMO Capital Markets reiterated an “outperform” rating and issued a $15.00 price objective on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Morgan Stanley raised their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Friday, June 21st. Finally, Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, July 18th. They set an “outperform” rating and a $14.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.